Thank you for speaking with us at SOT 2019
Posted: March 14, 2019
Diapharma is proud to offer an extensive line of biomarkers and antibodies for liver and kidney injury studies.
EMERGING EXPLORATORY BIOMARKERS FOR EVALUATING DRUG SAFETY
- The use of new biomarkers and new models can increase liver specificity and provide mechanistic information
- Defend the safety of your drug candidate and reduce unnecessary costs
- Prevent unnecessary withdrawal or clinical hold for promising new drug candidates
- Most importantly, prevent delay of new medications to the market
- M30 Apoptosense® ELISA detects hepatocyte apoptosis
- M65®/M65 Epideath® ELISAs detect both apoptosis and necrosis
- α-GST, Collagen IV, NGAL / Lipocalin, Cystatin C, and more
Research Use only in the U.S. and Canada
ML-00-00416Rev01